健康元：健康元药业集团股份有限公司2021年年度报告（英文版）.PDF

《健康元：健康元药业集团股份有限公司2021年年度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《健康元：健康元药业集团股份有限公司2021年年度报告（英文版）.PDF（291页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、 1 Important Notice I The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this annual report (the “Report”), and that there are no false representa

2、tions, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. II All directors of the company have attended the Board meeting. III Grant Thornton (Special General Partnership) Issued a standard unqualified audit report for the Company. I

3、V Mr. Zhu Baoguo (朱 保 国), the person-in-charge of the Company, and Mr. Qiu Qingfeng (邱 庆 丰), the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) declare that they hereby warrant the truthfulness, accuracy and completen

4、ess of the financial statements contained in the Report. V Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board resolution during the Reporting Period Based on the audit conducted by Grant Thornton (Special General Partnership), the Parent Company

5、 generated net profit of RMB 1,248,797,138.93, 10% of which was contributed to the statutory surplus reserve, namely RMB 124,879,713.89, the remainder of which, together with undistributed profits from last year RMB 564,932,141.19, subtracting cash dividends from last year RMB 288,675,388.05, is the

6、 current year Profits available for distribution to shareholders RMB 1,400,174,178.18. The Company plans to distribute cash dividends for the fiscal year 2021, based on the total number of shares for dividend distribution, which is defined by the total shares of Company, minus the shares in the Shar

7、e Repurchase Account, on the equity registration date designated by the annual profit distribution plan. The Company plans to distribute cash dividend of RMB 1.50 (tax inclusive) for every 10 shares of to all shareholders of the Company, and the remaining undistributed profits to be carried forward

8、to the following year. VI Risk declaration for the forward-looking statements Applicable N/A The Report contains forward-looking statements which involve the future plans, development strategies, etc. of the Company, yet do not constitute substantive undertakings of the Company to investors. Investo

9、rs should exercise caution prior to making investment decisions. VII Whether there is non-operating use of funds by the controlling shareholder and their related parties No VIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees No IX Whether mor

10、e than half of directors cannot warrant the truthfulness, accuracy and completeness of the Report disclosed by the Company No X Significant risk warnings There is no exceptionally significant risk that will have a material impact on the production and operation of the Company during the Reporting Pe

11、riod. In this report, the Company has elaborated on the risks and countermeasures that the Company may face in the course of production and operation, including industry policy risks, market risks, environmental risks, risk in price and supply of raw materials, R&D risks, risk of the normalization o

12、f Covid-19 pandemic. For more information, please refer to “Possible risks” part in Chapter III Management Discussion and Analysis. XI Others Applicable N/A XII The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding of the Chinese and English texts, the Chi

13、nese version shall prevail. 2 Table of ContentsChairmans Statement .3Financial Highlights .6Chapter 1 Definitions .8Chapter 2 Company Profile and Major Financial Indicators .10Chapter 3 Management Discussion and Analysis .15Chapter 4 Corporate Governance .60Chapter 5 Environmental and Social Respons

14、ibility .85Chapter 6 Major Events .110Chapter 7 Changes in Equity and Shareholders .124Chapter 8 Information on Preferred Shares .130Chapter 9 Information on Bonds .131Chapter 10 Financial Statements .132List of filingsThe Financial Statements signed and sealed by the person-in-charge of the Company

15、, the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department (the head of the accounting department)The original document of the auditors report sealed by the accounting firm and signed and sealed by the certified public accountants.The original copies

16、 of all documents and announcements of the Company which have been disclosed to the public on the website designated by CSRC during the Reporting Period 3 Dear shareholders,The year 2021, marking the opening year of the 14th Five-Year Plan, was a critical year for China to deepen the reforms of the

17、pharmaceutical and health systems. Starting there, the reform of the “three-med” linkage covering medicine, medical care, and medical insurance headed towards a deeper level. For the healthcare industry, the past year was full of unprecedented opportunities and challenges. The year 2021 was a year w

18、hen COVID-19 pandemic continued to spread around the world. The pandemic changed the habits and order of human society, regardless of national boundaries. We are experiencing a pandemic, a turnaround and a change unseen in a hundred years.Faced with the industry-wide “big test”, Joincare adheres to,

19、 as it always does, the mission of “For the health, For the future” and the vision of “Attentively developing high-quality medicines and innovative medicines”. Centered on medicine development, we were firmly implementing the dual-drive strategy of developing platforms of both innovative medicines a

20、nd high-barrier complex preparations. Oriented by the three-in-one goal of innovative transformation, integrated operation, and sustainable growth, we gave full play to the advantages of production-research integration and “APIs-preparations integration” across the entire industry. We sought “opport

21、unities” from “crisis” and pursued growth while ensuring stability. We united as one, worked hard, and finally successfully achieved our annual business goals and targets, achieving double-digit growth in both revenues and profits given that we have been continuously increasing investments in R&D.In

22、 2021, Joincare realized total revenues of RMB 15,904 million, representing a year-on-year increase of approximately 17.62%; realized a net profit attributable to shareholders of listed companies of RMB 1,328 million, representing a year-on-year increase of approximately 18.57%; and realized a net p

23、rofit attributable to shareholders of listed companies after deduction of the extraordinary gains and losses of RMB 1,225 million, representing a year-on-year increase of approximately 26.72%.Robust financial performance builds a solid foundation for us to generate higher returns for our shareholder

24、s. We attach great importance to our shareholder returns. In addition to completing the first share repurchase mandate with a total amount of RMB700 million in the secondary market in September 2021, we launched a new share buyback plan in the secondary market with a mandate of total amount of RMB 3

25、00 million to RMB600 million at the end of the reporing period; those share buyback mandtes illustrate the sincere confidence of the Borad and the management level in the intrinsic vaule of Joincare. Based on our operating results and overall financial position in 2021, the Board of Directors propos

26、e that we continue to adopt a stable profit distribution scheme. Specifically, a cash dividend of RMB 1.50 (tax inclusive) will be distributed to all shareholders for every 10 shares, based on the total number of shares for dividend distribution, which is defined by the total shares of Company, minu

27、s the shares in the Share Repurchase Account, on the equity registration date designated by the annual profit distribution plan.The profit distribution scheme for 2021 is yet to be reviewed and approved at the Companys 2021 Annual General Meeting.In 2021, our main business structure and product matr

28、ix have been continuously optimizing, making the Groups advantages of endogenous growth much more significant.We achieved an obvious sales growth in the segment of chemical drug preparations, and an especially rapid year-on-year sales growth in key advantageous fields, such as respiratory, gastroent

29、erology and gonadotropic hormones. In the segment of APIs, our high-end characteristic APIs steadily gained more market shares and profits. We have been continuing doing great jobs in pipeline commercialization and recording increased sales volumes in our inhalation preparations segment, reconfirmin

30、g the growth momentum and our status as a leader of the inhalation medicine market niche in China.The Sale Volumes of The Ilaprazole series, one of our innovative medicines, and of Leuprorelin Acetate Microspheres for Injection, one of our high-barrier complex preparations continue to grow rapidly,

31、providing a strong engine for the rapid development for Joincare.In terms of product innovation, In the innovation development in line with the trend of the times, we gradually worked out a set of mature system, and continuously polished and optimized along each dimension, not letting go of any oppo

32、rtunity for leapfrog development under the tone of progressive innovation. We continued to significantly increase our R&D investment for several years, from RMB 609 million in 2016 to RMB1,850 million Chairmans Statement 4 in 2021, more than tripling in five years. “Taking the needs of patients as o

33、ur responsibility and being ambitious to be the pioneer”, we have developed innovative R&D technology platforms for high-barrier complex preparations, including inhalation administration, antibody, and sustained-release microspheres. In 2021, the R&D of many innovative medicine products in the Group

34、s pipeline made significant progress.We are expanding our business territory at a steady pace. In 2021, Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), jointly developed by the Institute of Biophysics of the Chinese Academy of Sciences and Joincare, achieved milestones in terms of both R&D and

35、 commercialization. Currently, we are actively promoting the launch of V-01 to the market, hoping to contribute to the world-wide fight against the COVID-19 epidemic at the earliest possible time. As Joincares first product to conduct the phase III global multi-center clinical trials, the smooth pro

36、gress of V-01s phase III clinical trials have also accumulated richer resources and experience in organizational management, partnerships, team capabilities and registration applications for the internationalization of our innovative medicines. In 2021, Joincare Biopharmaceutical Research Institute

37、was established. We successively built 6 R&D platforms of industrial strain improvement, synthetic biology, biocatalysis, fermentation scale-up, product extraction, and biochemical APIs. In addition, we signed a strategic cooperation agreement with Tencent Quantum Lab to joint our efforts in establi

38、shing a system enabled by quantum computing and AI for research on microbial synthetic biology and R&D of relevant drugs. We will apply AI technology to better serve the Groups R&D and innovation, and boost the development and upgrading of Chinas medical and healthcare industry.In 2021, in terms of

39、business model innovation, we strive to embrace a digital marketing mode.Our “Healthy Lung” Challenge for the World COPD Day launched on TikTok was a precedent for digital marketing in the industry. In China, the rate of awareness and rate of standardized diagnosis and treatment of Chronic obstructi

40、ve pulmonary disease (COPD) and similar chronic respiratory diseases are low, but the patient population is quite large. Joincare has bravely stepped out of the “comfort zone”, create a “friend zone” and build an “ecosphere”. With the clear principle of “patient-centered”, We strive to empower all l

41、inks including education, screening, diagnosis, treatment, and medication monitoring, form a closed-loop consisting of doctors, hospitals, patients and drug companies, and explore the external huge market of chronic disease management with private traffic, so as to realize real-time interaction betw

42、een consumers and brands, and inject new vitality to commercialization of the Company.Only when we share the same frequency can we resonate. While focusing on our own development, the Group always persists in contributing to the social welfare business and actively undertakes social responsibilities

43、 We pay great attention to our sustainable development, and actively focus on the internal regulatory environment and external policy guidance. Considering Chinas 14th Five-Year Plan and the local governments development plan, the Group has formulated a CSR strategy and goals adapting to its current

44、 business situation. We adhere to social welfare undertakings and strive to make achievement in both enterprise profits and social benefits.The inhalation medicine products are the best and most effective therapy methods for respiratory diseases, such as asthma and COPD, and the R&D investments in t

45、his market niche are highly recommended by the Chinese government. However, due to the high barriers to the R&D and production of inhalation medicine products, the market shares have been dominated by foreign manufacturers for a long time. In March 2021, the National Drug Reimbursement List (2020) w

46、as officially implemented. Joincares blockbuster product, Levosalbutamol Hydrochloride Nebuliser Solution, as the only made-in-China inhalation preparation included in the List for negotiation led by National Health Security Administration, started to benefit more patients with respiratory diseases.

47、 In June 2021, Joincares three inhalation preparation products, including “Budesonide Suspension for Inhalation” (雾舒), “Compound Ipratropium Bromide Solution for Inhalation” (舒坦琳), and “Ipratropium Bromide Solution for Inhalation” (丽雾安), were listed in the fifth round of the national centralized dru

48、g procurement program. This enabled more Chinese people to get high-quality inhalation preparations at a more affordable price.In 2021, our footprint for public welfare for chronic diseases prevention and treatment further expanded. Since the end of 2018 until today, the “Access to Public Welfare fo

49、r Chronic Diseases Prevention and Treatment Program”, established jointly by the us and the Livzon Group, has been implemented in various regions, including Sichuan Province, Shanxi Province, Gansu Province, Jilin Province, Tibet, Henan Province, Anhui Province, Hunan Province and Jiangxi Province,

50、and delivered pharmaceuticals needed urgently by middle and elder age patients with chronic diseases.In 2021, Henan was hit by a flood and drew nation-wide concerns. To help the flood-stricken areas, Joincare and Livzon Group 5 Annual Report2021quickly joined hands to donate a total of RMB 10 millio